Share
Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Boston Convention and Exhibition Center, Boston, Massachusetts
November 08, 2022 - November 12, 2022
The SITC Annual Meeting brings together a global community of scientists focused on cancer immunotherapy and tumor immunology. Join us at booth #313 to explore our immuno-oncology research tools, 2-D and 3-D patient-derived cancer models, EMT and THP-1 reporter cell lines, human primary cells, cancer panels, and more!
Want to speak to one of ATCC’s representatives about a product or service? Contact us so we can discuss your needs.
Human Cancer Models Initiative
ATCC is collaborating with the Human Cancer Models Initiative (HCMI) to offer scientists a wide variety of next-generation 2D and 3D patient-derived in vitro cancer models representing common as well as rare and understudied examples of cancer from numerous tissues. To enhance their clinical relevance, the sequence data and patient clinical information for each model is available to the research community. These HCMI models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Find next-generation modelsBrowse our cell lines for immuno-oncology research
Immunology research tools
Boost your immuno-oncology research with cell lines and cell culture reagents focused on advancing areas such as cancer cell-directed therapies and immune cell-directed therapies. Our collection of primary cells and continuous cell lines includes immune cells, CD34+ and CD14+ progenitor cells, primary mononuclear cells, lymphocytes, and leukocytes.
Find immune cells
Primary human immune cells
ATCC primary immune cells are able to support complex, physiologically relevant research projects, including cancer immunology studies, toxicity screening, transplantation and graft rejection studies, and vaccine and drug development. Our portfolio boasts a variety of human primary immune cells derived from a wide range of donors.
Order primary immune cells
THP-1 reporter cells
To support the development of immunotherapies, ATCC introduced luciferase reporters containing the response element of immunologically important transcription factors into the THP-1 cell line. These advanced models provide a robust and highly sensitive means to measure immune activation through in vitro bioluminescence measurements.
Order THP-1 reporter cell lines
Immuno-oncology Research Tools
The development of immunomodulatory drugs and biologics dictate a clear need for human cell-based models to evaluate immune activation. To answer this need, ATCC provides a large collection of fully characterized and authenticated continuous cell lines, human primary cells, reporter-labeled cells, and advanced cell models.
Find immuno-oncology resources
Cancer panels
ATCC offers a wide variety of cancer cell lines for use in research related to cancer genetics, early detection methods, and effective treatment of disease. Panels of these cell lines offer researchers the value of several lines for comprehensive studies. Explore our panels by tissue type, genetic mutation, or molecular signature.
Order cancer panels
Isogenic cells
Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for elucidating molecular pathways of cancer progression.
Explore isogenic cells
Matched normal and cancer cells
Cancer research starts out with the investigation of the biological differences between normal, healthy cells and cancerous cells. That's why ATCC offers authenticated tumor-derived cell lines matched to normal cells from the same donor to provide you with a valuable starting point for your cancer studies.
Get the cells
EMT reporter cells
Epithelial-mesenchymal transition (EMT) and its reverse, MET, can play critical roles in promoting metastasis and invasion and contribute to drug resistance in carcinoma. ATCC used CRISPR gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.
Enhance your research
Next-generation cancer models
ATCC is offering scientists a wide variety of next-generation patient-derived in vitro cancer models, including organoids, which will include both common as well as rare and understudied examples of cancer from numerous tissues. These advanced models are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research.
Discover howContact us today!
Your ATCC sales representative stands ready to discuss your research needs and provide you with personalized care in sourcing reference materials, managing requests, and providing sales quotes. Please complete our form to let us know how we can help, and we will start working on your needs right away.
